All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lupus Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-10-11T15:18:37.000Z

Visual abstract | The TULIP trials: Post hoc analysis of sustained glucocorticoid tapering with anifrolumab management of SLE

By Ella Dixon
Oct 11, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new development in systemic lupus erythematosus.

Bookmark this article

The Lupus Hub is happy to present a visual abstract representing data from a post hoc analysis of the phase III TULIP-1 and TULIP-2 trials (NCT02446912 and NCT02446899), which evaluated the use of anifrolumab to support sustained glucocorticoid tapering in patients with systemic lupus erythematosus.1 Glucocorticoids remain the standard of care in ~80% of patients, but prolonged use is associated with toxicity and adverse events. Tapering glucocorticoid use in patients with SLE patients can lead to an improvement in patient-reported outcomes.1


 

Visual Abstract

To download this visual abstract, click below.

Download here

  1. Bruce IN, van Vollenhoven RF, Morand EF, et al. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post-hoc analysis of the TULIP-1 and TULIP-2 trials. Rheumatology (Oxford). Online ahead of print. DOI: 10.1093/rheumatology/keac491

More about...
AnifrolumabSystemic lupus erythematosusTULIP-1TULIP-2

Related articles

Add bookmark

Management of general systemic lupus erythematosus

This article summarizes the 2019 recommendations for the management of SLE, along with recent developments from subsequent clinical trials.

Sep 15, 2022
Add bookmark

Management of general systemic lupus erythematosus

This article summarizes the 2019 recommendations for the management of SLE, along with recent developments from subsequent clinical trials.

Sep 15, 2022
Add bookmark

Management of lupus nephritis

In their article published in Nephrology, Dialysis, Transplantation late in 2021, Anders et al., of ERA, sought to identify and clarify the differences between two guidelines. We will summarize this publication, along...

Sep 14, 2022
Add bookmark

Management of lupus nephritis

In their article published in Nephrology, Dialysis, Transplantation late in 2021, Anders et al., of ERA, sought to identify and clarify the differences between two...

Sep 14, 2022

Newsletter

Subscribe to get the best content related to lupus delivered to your inbox